Mitotane occupies a genuinely singular position in oncology — it's the only medicine specifically approved for adrenocortical carcinoma, an extremely rare cancer of the adrenal gland, which means there's no real alternative therapy for physicians to fall back on if a reliable supply isn't available. Because the patient population is so small and geographically scattered, most buyers sourcing this drug are specialist endocrine-oncology centers rather than general hospitals, and sourcing reliability tends to matter far more to them than price competitiveness.
- Approved indication: Adrenocortical carcinoma (adrenal cortex cancer), both as adjuvant therapy after surgery and for inoperable, recurrent, or metastatic disease
- Mechanism: Selectively cytotoxic to adrenal cortex cells, causing adrenal tissue destruction and suppressing steroid hormone production from tumor cells
- Treatment duration: Often continued for months to years, requiring consistent long-term supply rather than a single course
- Buyer profile: Specialist endocrine-oncology centers and university hospital cancer programs — a narrow but consistent institutional buyer base globally, given how rare this cancer is
Because Mitotane destroys adrenal tissue as part of its mechanism, it inevitably causes adrenal insufficiency in the patient — meaning treatment isn't just about giving the drug, but managing the hormone-replacement therapy that has to run alongside it under close endocrinology supervision.
- Adrenal insufficiency: Expected and requires steroid replacement therapy (hydrocortisone) with dose titration managed by an endocrinologist throughout treatment
- Neurotoxicity: Can occur at higher doses — symptoms include dizziness, lethargy, and confusion, requiring dose adjustment if they appear
- Pregnancy: Strictly contraindicated — severe, well-documented teratogenicity risk
- Drug level monitoring: Blood mitotane levels are typically monitored periodically to guide dosing and avoid toxicity
- Hepatic function: Regular liver function monitoring recommended given known hepatotoxicity risk
Given how few institutions worldwide treat adrenocortical carcinoma regularly, we maintain closer, more direct communication with our source manufacturer specifically for this SKU than we do for higher-volume oncology products — supply continuity for a patient already months into treatment matters more here than for almost any other drug in our catalogue.
- Certification: WHO-GMP sourced manufacturing
- Batch-specific testing: Purity and potency validated for every batch
- Supply-continuity focus: Given the rare-disease context, we prioritize proactive communication with manufacturers on this specific SKU to avoid supply gaps for patients already on long-term therapy
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
| CTD/ACTD Dossier |
Available on request, relevant for named-patient import pathways |
Stock status: On request | Quote turnaround: Confirm quantity and destination for pricing
- Logistics: Standard export logistics — room-temperature stable, no cold chain required
- Coverage: Global, serving a small but geographically dispersed set of specialist centers
- Tracking: Full shipment tracking included
Because adrenocortical carcinoma is so rare, named-patient or compassionate-use import is the standard, expected pathway in nearly every country we serve — this isn't an exception process for Mitotane, it's essentially the normal route, and our team has direct hands-on experience navigating it.
- Institutional buyers: Specialist endocrine-oncology center procurement
- Named-patient/compassionate-use import: The primary access pathway in most markets given the drug's orphan-disease status
- First-time importer support: Direct guidance through documentation requirements for rare-disease named-patient imports
What is Mitotane used for?
It treats adrenocortical carcinoma, a rare cancer of the adrenal gland, and is the only medicine specifically approved for this condition.
Get Mitotane price from a GMP-compliant Indian supplier — how?
Send quantity and destination country for a verified quote.
Why does it require hormone replacement therapy?
Mitotane destroys adrenal tissue as part of its mechanism, causing adrenal insufficiency that must be managed with steroid replacement.
Is it available for named-patient import?
Yes, this is the standard access pathway in most countries given how rare the treated cancer is.
Who supplies Mitotane from India?
WHO-GMP certified manufacturing with a focus on long-term supply continuity for ongoing patient treatment.
